Pediatric Oncology: Summary of Guidances and Meetings
Guidances
Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment
Meetings
15 Sep: Pediatric Advisory Committee
Will discuss pediatric-focused safety reviews for medications related to acute dystonia associated with ADHD, acute hyperkinetic movement disorder associated with combined use of ADHD stimulants and antipsychotics
22-23 Oct: Pediatric Dose Selection Public Workshop ($50)
Will discuss current methods and future approaches, and how to address gaps in pediatric dose selection that occur because of an inability to perform certain studies in pediatric patients
Categories
- Blog Posts (65)
- Guest Blogs (18)
- Member Blogs (24)
- Survivorship Matters Blog (9)
- CAC2 News (21)
- Collaborative Achievements (13)
- Community News (170)
- News Digest (130)
- Research Explained (10)
- Webinars (61)
Tags
#CancelChildhoodCancer (1)
Advocacy (47)
Annual Summit (7)
Awareness (20)
AYA (2)
Best Practices (12)
Biorepositories (2)
CAC2 News (7)
CAC2 Project Incubator (1)
CAC2 Projects (11)
Call to Action (24)
Cancer Moonshot (1)
Clinical Trials (10)
COG (2)
Collaboration (11)
Comparative Oncology (1)
Data (15)
Delayed Diagnosis (2)
Digest (12)
Drug Development (12)
Drug Shortages (2)
Ethics (1)
Family Support (14)
FDA (1)
Funding Research (6)
Genomics (6)
Industry Perspective (5)
Member Access (12)
NCI (3)
Nutrition (1)
Patient-Reported Outcomes (1)
Prevention (5)
Psychosocial Support (4)
Rare and Ultra Rare Cancer (1)
Rare Cancers (1)
Regulations (3)
Research (38)
Research Advocacy (1)
Survivorship (26)
Venture Philanthropy (3)